Introduction
Acute promyelocyƟc leukemia (AML-M3) represents about 5% to 10% of childhood acute myeloid leukemia and is characterized by the clonal expansion of leukemic blasts blocked the promyelocyƟc stage of myeloid differenƟaƟon. 1 Nearly all cases of AML-M3 are characterized by the presence of t(15;17) chromosomal translocaƟon, which involves the fusion of the PML gene on chromosome 15 to the reƟnoic acid receptor alpha (RARA) on chromosome 17.
2 AML-M3 can be disƟnguished from other subtypes of AML by virtue of extent of its response and overall outcome as a result of differenƟaƟon therapy with all-trans-reƟnoic acid (ATRA). 3 Many clinical trials convincingly demonstrated the benefits of ATRA in paƟents with AML-M3. 4 The outcome of AML-M3 has evolved during the last 40 years from one of the most fatal leukemia to one that is highly curable aŌer entrance of ATRA. 5 ATRA, a naturally occurring derivaƟve of vitamin A, exhibits profound anƟ-proliferaƟve and pro-differenƟaƟng effects on a variety of tumor cells in vivo and in vitro by modulaƟng gene transcripƟon. [6] [7] [8] Cellular reƟnoic acid-binding protein-II (CRABP-II) appears to funcƟon as a carrier of bound ATRA from the cytoplasm to the nuclear RARA. 2, 7 ReƟnoic acid receptors (RARs) belong to the steroid/thyroid hormone receptor gene family, which encodes proteins that act as ligand-dependent regulators of gene transcripƟon. 2, 7 The PML/RARA chimeric protein has oncogeneic properƟes both in vivo and in vitro.8,9 Treatment with ATRA induces differenƟaƟon of the leukemic blasts and results in hematological remission. 1, [10] [11] [12] However, although ATRA provides an important benefit to paƟents with AML-M3, there are significant side effects.
prolonged vaginal bleeding following menstruaƟon was admiƩed to Shafa hospital, Ahvaz. The paƟent was pancytopenic and her coagulaƟon profile was also abnormal. The bone marrow aspiraƟon study was compaƟble to diagnosis of acute promyelocyƟc leukemia (AML-M3). The paƟent iniƟally received supporƟve care such as blood, platelet, and fresh frozen plasma transfusion. AŌer stabilizaƟon, ATRA was started with dose of 45mg/m2/day. During the treatment course with ATRA, the paƟent's complete blood count, coagulaƟon profile, renal funcƟon, liver funcƟon, and electrolytes were checked daily.
On hospital day 12, the paƟent developed fever, respiratory distress, hypertension, and tachycardia. Chest radiography revealed bilateral intersƟƟal infiltraƟons and pleural effusions (figure1). The paƟent´s arterial blood gas analysis showed respiratory acidosis with parƟal renal compensaƟon. The paƟent´s ATRA was hold and immediately high-dose intra venous dexamethasone (12mg/12hr) was started with suspicion of reƟnoic acid syndrome. With worsening of the paƟent´s hypoxemia and pulmonary infiltraƟons, she needed to receive mechanical venƟlaƟon support. High blood pressure was treated with diureƟcs and fluid limitaƟon. On physical examinaƟon, the paƟent had bilateral ralles, and intercostal and supracostal retracƟons. The paƟent´s anƟbioƟc coverage included vancomycin and imipenem. All cultures were negaƟve. Despite the efforts, the paƟent´s condiƟon worsened, and pulmonary hemorrhage, cardiac failure, and hypotension were developed. At this point, vassopressor and cardiac inotropic agents started. Because of cardiac dysfuncƟon and severe pulmonary hemorrhage, the paƟent died aŌer 24 hours.
Discussion
Although ATRA is generally well tolerated, some paƟents develop the reƟnoic acid syndrome manifested by unexplained fever, weight gain, respiratory distress, intersƟƟal pulmonary infiltrates, pleural and pericardial effusion, episodic hypotension, and acute renal failure. 3, 11, 15, 16 This syndrome is the most serious toxicity of ATRA and is oŌen, but not always, associated with development of hyperleukocytosis.
14 It has been suggested that paƟents with a white blood cell (WBC) count exceeding 5000/μL on day 1, 6000/μL on day 5, 10000/μL on day 10, or 15000/μL on day 15 are at high risk for development of the syndrome. 5 The diagnosis of reƟnoic acid syndrome is made on clinical grounds by the presence of at least three of the following signs in the absence of other causes: fever, weight gain, respiratory distress, lung infiltrates, pleural or pericardial effusion, hypotension, and renal failure. 4, 5, [17] [18] [19] There were no pretreatment predictors of the syndrome and there is no uniform agreement on its opƟmal treatment in randomized clinical trials that have evaluated therapy. 3, 4, 12, 20 Based on anecdotal evidences when the diagnosis of reƟnoic acid syndrome is made, corƟcosteroids (prednisolone or dexamethasone) are given immediately, and administraƟon of ATRA is disconƟnued. [2] [3] [4] [5] 11, 12, 14 Neither the pathogenesis nor the opƟmal way to prevent or treat the syndrome has been determined. 4, 7, 18, 21 In newly diagnosed AML-M3 paƟents treated with ATRA, the incidence of reƟnoic acid syndrome varies from 5% to 27% based on recent studies. Also, the onset Ɵme onset of reƟnoic acid syndrome varies. 12 The reported median Ɵme to the occurrence of reƟnoic acid syndrome is 7-12 days aŌer ATRA therapy. 14 This syndrome is usually, but not necessarily, associated with hyperleukocytosis and a rapid rise in the leukocyte count. 4 ReƟnoic acid syndrome is associated with a high mortality ranged from 5% to 29%. 2 However, the mortality rate of paƟents with the syndrome likely reflects the Ɵme of recogniƟon and insƟtuƟon of corƟcosteroids (prednisolone or dexamethasone). 12, 14, 22 Clinically, the symptom complex most closely resembles the capillary leak syndrome associated with the administraƟon of various cytokines, parƟcularly interleukins (IL). 2, 5, 12 The proposed mechanisms could involve changes in the cytokine secreƟon and adhesive qualiƟes of acute promyelocyƟc cells (APL) cells during ATRA-induced differenƟaƟon. 2, 16, 18 Drug-induced release of vasoacƟve cytokines (IL-1β, IL-6, IL-8, and the tumor necrosis factor) from differenƟaƟng leukemic cells would explain certain manifestaƟons such as fever, generalized weight gain, and episodic hypotenƟon. 11, 18 Organ infiltraƟon by AML-M3 cells found in postmortem studies of the reƟnoic acid syndrome suggests that drug-induced maturaƟon of previously undifferenƟated leukemic cells, although sƟll dysfuncƟonal, could impair certain funcƟons of mature neutrophils, including their migratory capabiliƟes. 15 ,1820 MigraƟon of these cells into Ɵssues, such as the lung and kidney, could explain the clinically observed respiratory distress and occasional renal impairment. 5, 18 Finally, leukocyte adherence to capillary endothelial cells and to the extracellular matrix is mediated by integrins (leukocyte adhesion receptors). Genes encoding integrins were recently found to be up-regulated by reƟnoic acid. 2, 5, 7, 12, 18 Conceivably, ATRA increases integrin expression on the leukemic cell surface; this would enhance the cell's adherence to capillary endothelium and would promote focal endothelial leakage. 2, 5, 7, 12, 18 Methylprednisolone rapidly inhibits AML-M3 cell aggregaƟon in a dose-dependent manner, consistent with its prompt clinical effecƟveness in vivo. 5, 7 Radiologic features may also be explained by the proposed hypothesis for ATRA syndrome pathophysiology. 18 Most of the paƟents with reƟnoic acid syndrome show cardiomegaly, widening of the vascular pedicle width, increased pulmonary blood volume, ground-glass opacity, and pleural or pericardial effusion. 18 PaƟents with microgranular variant promyelocyƟc leukemia appear to be protected from the syndrome, but the reason(s) is not clear.5 Based on recent reports, the iniƟal WBC count as well as the rate of rise is not staƟsƟcally correlated with the development of the syndrome.6 Usual dose of ATRA in paƟents with AML-M3 is 45mg/m2/day. 1 Strategies to prevent the syndrome with administraƟon of a lower dose of ATRA (25mg/m2/day) resulted in a similar cure rate and toxicity profile, including a similar incidence of reƟnoic acid syndrome as the standard dose. 5, 14, 21 Several observaƟons suggest that ATRA need not necessarily be disconƟnued if the reƟnoic acid syndrome develops and corƟcosteroids insƟtuted at the earliest sign or symptom. However, the success of the approach may depend on the severity of the syndrome and the rapidity of steroids administraƟon. 19 ProphylacƟc corƟcosteroids could not be recommended for rouƟne use currently.
Frankel et al first described this syndrome in nine (25%) of 35 paƟents who were newly diagnosed with APL and treated with ATRA.
14 ReƟnoic acid syndrome developed in paƟents at an average of 7 days (range, 1-22 days) aŌer the start of ATRA.5,14,18 The major clinical manifestaƟons of ATRA syndrome included respiratory distress (80%), fever(37%), and generalized edema(47%).1,14,15,17,18 Leukocytosis is found in 46% of the paƟents.5 All paƟents show chest radiographic abnormaliƟes when clinical symptoms develop. 18 Chest radiographs show increased cardiothoracic raƟo in 64% of the paƟents, increased vascular pedicle width in 76%, increased pulmonary blood volume in 82%, ground-glass opacity in 57%, consolidaƟon in 60%, and nodules in 60% of the paƟents. 18 Pleural effusion is noted in 75% of the paƟents either unilaterally or bilaterally. 18 Pulmonary hemorrhage is developed in about 20% of the paƟents during the course of reƟnoic acid syndrome.18,5 When pulmonary hemorrhage occurs, diffusely bilateral and poorly defined nodules, ground-glass opacity, and consolidaƟon develop on chest radiography. [16] [17] [18] In one study on 44 paƟents with APL who developed the reƟnoic acid syndrome, a median Ɵme of 11 days aŌer start of ATRA (range, 2-47 days) was reported and the maximum WBC count ranged from 6800/μL to 72000/μL (median: 31000/ μL). Mechanical venƟlaƟon is required in about 26% of paƟents with this syndrome. [3] [4] [5] 18 Among 167 paƟents with newly diagnosed AML-M3 treated with ATRA alone for inducƟon, reƟnoic acid syndrome developed in 26%.
12, 17 The symptoms generally begin within the first thirty days of ATRA therapy, the median Ɵme to onset is 7 days. 2 An overall incidence of 15% was reported by the Europian APL group, with a mortality rate of 8% of paƟents with the syndrome. No difference in the incidence of the syndrome was observed among paƟents treated with concurrent versus sequenƟal ATRA and chemotherapy.
12 Definite outcome of reƟnoic acid syndrome and efficacy of treatment with corƟcosteroids are not obvious but early diagnosis of the syndrome manifestaƟons and immediate treatment with corƟcosteroids aŌer the diagnosis of reƟnoic acid syndrome may improve the outcome. [1] [2] [3] [4] 11, 12, 14, 16 Prednisolone is the treatment of choice in reƟnoic acid syndrome (20-40mg/kg, divided doses). 2, 3, 5 AŌer treatment, the radiologic features and clinical symptoms gradually improve in 67% of the paƟents but 23% of the paƟents fall into acute respiratory distress. 18 All paƟents who had reƟnoic acid syndrome with acute respiratory distress died despite intensive care on a venƟlator.5 All paƟents with AML-M3 who developed the syndrome and pulmonary hemorrhage during ATRA treatment died.
18

Conclusion
Early recogniƟon of reƟnoic acid syndrome is important because early intervenƟon with high doses of corƟcosteroid appear to abort the progression of this syndrome. 3, 4, 5, 7, 18 Although the imaging features are not characterisƟc, in combinaƟon with the clinical history, they may aid in early recogniƟon of the reƟnoic acid syndrome and thus to its prompt resolusion. 18 In a paƟent with AML-M3 receiving ATRA therapy, this syndrome should be considered when chest radiographs show cardiomegaly, vascular distenƟon, ground-glass opacity, and pleural or pericardial effusion in the presence of a clinical history including respiratory distress, unexplained fever, hypotension, and generalized edema. 5, 12, 18 If moderate or severe reƟnoic acid syndrome develops, it is prudent to disconƟnue ATRA. 12 When the syndrome resolves, ATRA can safely be restarted in most paƟents; however, close observaƟon is warranted. 5, 8, 13 
